New Research from Memorial Sloan Kettering Institute Offers Clear Path to Improved Immunotherapy by Identifying Opposing Subtypes of Regulatory T Cells
NEW YORK, NY – For decades, the role of regulatory T (Treg) cells in cancer has been a perplexing paradox, particularly in colorectal cancer. While these immune cells, which typically act as "brakes" on the immune system, are often associated with worse outcomes in most solid tumors due to their ability to dampen the body’s anti-cancer response, colorectal cancer has stubbornly stood as a puzzling exception. In this widespread disease, an abundance of Treg cells has frequently been linked to longer patient survival, leaving researchers grappling with a fundamental question: why does colorectal cancer defy the established immunological rule?
Now, a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally offered a clear, compelling explanation, poised to revolutionize immunotherapy strategies. The pivotal discovery reveals that not all Treg cells are created equal; instead, their impact hinges on distinct subtypes with diametrically opposed functions within the tumor microenvironment. This nuanced understanding promises to significantly improve treatment for the vast majority of colorectal cancer patients and potentially extend to other cancers affecting barrier tissues such as the skin, mouth, throat, and stomach lining.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." The findings, published in the prestigious scientific journal Immunity, mark a critical turning point in our understanding of tumor immunology and pave the way for highly targeted therapeutic interventions.
Decades of Relentless Research Culminate in a Breakthrough
This seminal work is the culmination of more than two decades of dedicated research by Dr. Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His pioneering investigations have been instrumental in establishing the fundamental principles of Treg cell biology, particularly their crucial role in maintaining "immune tolerance." This vital function allows the immune system to accurately distinguish between harmful pathogens and benign entities – such as the body’s own cells, beneficial microbes, and everyday foods – thereby preventing autoimmune attacks and unnecessary inflammation. Over the years, Dr. Rudensky’s laboratory has systematically unraveled the intricate mechanisms governing how Treg cells are generated, how they execute their immunosuppressive functions, and, crucially, how they influence the complex trajectory of cancer development.
The current study, building on this rich foundation of knowledge, was a collaborative effort led by an exceptional team of first authors. Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab, brought his expertise in experimental immunology to delineate the functional differences between Treg subtypes. Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now contributing his insights at the Icahn School of Medicine at Mount Sinai, provided critical clinical perspective, bridging basic science with patient care. Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author, spearheaded the complex data analysis, leveraging advanced computational techniques to decipher the intricate cellular landscape of tumors. This multidisciplinary approach, combining immunological experimentation, clinical understanding, and sophisticated computational biology, was essential to unlocking the mysteries of Treg heterogeneity in colorectal cancer.
A Laser Focus on the Most Common Form of Colorectal Cancer
Colorectal cancer (CRC) remains a formidable public health challenge. According to the American Cancer Society, it ranks as the second leading cause of cancer-related death when statistics for men and women are combined, underscoring the urgent need for more effective treatments. While significant strides have been made in cancer therapy, many patients still face limited options.
A critical aspect of this study’s impact lies in its targeted focus. The researchers concentrated on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancers with proficient mismatch repair (MMRp). These tumors represent a substantial 80% to 85% of all colorectal cancer cases. Historically, this group of cancers has presented a particularly difficult challenge because they typically respond poorly to checkpoint inhibitor immunotherapies – a class of drugs that have revolutionized treatment for many other cancer types by unleashing the body’s immune system.
This stands in stark contrast to the less common, yet often more treatable, microsatellite instability-high (MSI-H) and mismatch repair deficient (MMRd) colorectal cancers. Earlier research, including significant contributions from MSK, demonstrated that checkpoint inhibitors can be remarkably effective against MSI-H/MMRd tumors, often enabling patients to forgo more aggressive treatments like surgery, chemotherapy, and radiation. The disparity in treatment response between these two CRC subtypes has highlighted a critical unmet need for the majority of patients with MSS/MMRp colorectal cancer, making the MSK team’s discovery particularly impactful for a vast patient population.
Two Types of Treg Cells: An Immune Tug-of-War with Opposite Effects
To dissect the immunological intricacies that differentiate common colorectal cancers, the research team employed a sophisticated mouse model. This model, meticulously developed at MSK, faithfully replicates the genetic alterations, tumor behavior, and complex immune microenvironment observed in human colorectal tumors, providing a robust platform for mechanistic studies.
Through a series of detailed and elegant experiments, the researchers made a pivotal observation: tumor-associated Treg cells do not represent a homogeneous population but rather segregate into two principal groups. The distinguishing factor? The production of a crucial signaling molecule, or cytokine, called interleukin-10 (IL-10). One group of Treg cells actively produces IL-10, while the other does not.
By selectively ablating, or removing, each of these distinct Treg cell groups in controlled experimental settings, the team uncovered profound and opposing effects on tumor growth:
-
IL-10-positive Treg cells: The Protective Guardians. These cells emerged as beneficial players in the colorectal cancer microenvironment. They actively help slow tumor growth by mitigating the activity of Th17 cells, another type of immune cell that produces interleukin 17 (IL-17). Critically, IL-17 functions as a growth signal for tumors, promoting their proliferation. By dampening the Th17/IL-17 axis, IL-10-positive Treg cells act as a brake on tumor progression. Interestingly, these protective Treg cells were found to be more prevalent in the healthy tissue immediately surrounding the tumor, suggesting a role in maintaining local immune homeostasis. When these IL-10-positive Treg cells were experimentally removed, tumors grew at an accelerated pace, definitively proving their anti-tumorigenic role.
-
IL-10-negative Treg cells: The Immunosuppressive Enablers. In stark contrast, the IL-10-negative Treg cells exerted a detrimental effect on tumor control. These cells actively suppress powerful immune defenders, most notably CD8+ T cells, which are renowned for their potent cancer-fighting abilities. By neutralizing the cytotoxic activity of CD8+ T cells, these harmful Treg cells create an immunosuppressive environment that allows tumors to evade immune surveillance and thrive. Unlike their beneficial counterparts, this deleterious subtype was predominantly localized within the tumor itself, strategically positioned to exert maximum immunosuppression. The experimental elimination of IL-10-negative Treg cells led to a significant reduction in tumor size, underscoring their role in fueling tumor growth.
Patient Data Resoundingly Confirms the Laboratory Discoveries
To validate these compelling findings from their preclinical models, the MSK team meticulously analyzed tumor samples obtained directly from human colorectal cancer patients. This crucial translational step confirmed the presence of the two distinct populations of IL-10-positive and IL-10-negative Treg cells in human disease, mirroring their observations in the mouse model.
Further reinforcing the clinical relevance, the researchers conducted an extensive analysis of outcomes for more than 100 colorectal cancer patients. The results were striking and unequivocal: patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells demonstrated significantly longer survival rates. Conversely, patients whose tumors were enriched with the harmful IL-10-negative Treg cells experienced poorer clinical outcomes.
"This research shows how important these positive cells are," affirms Dr. Huang. "And it highlights the urgent need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment underscores the profound shift in therapeutic strategy that this discovery advocates: moving away from indiscriminate Treg depletion towards a highly nuanced and targeted approach.
Targeting CCR8: A Promising New Treatment Strategy Emerges
The revelations from this study not only resolve a long-standing immunological enigma but also illuminate a clear, promising path forward for improving treatment for the vast majority of colorectal cancer patients, particularly those with MSS/MMRp tumors who currently have limited immunotherapy options.
A critical finding with immediate therapeutic implications is that the harmful IL-10-negative Treg cells express exceptionally high levels of a specific protein called CCR8. These are precisely the cells responsible for suppressing the anti-tumor immune response, and their high expression of CCR8 makes them a vulnerable and attractive target. Furthermore, these CCR8-expressing, immunosuppressive Tregs are primarily localized within the tumor microenvironment, offering a potential for highly localized targeting.
This discovery seamlessly integrates with earlier groundbreaking work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. Their prior research demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That foundational work originally proposed that antibodies designed to target CCR8 could be utilized to selectively deplete these harmful Treg cells. The therapeutic promise of such an approach lies in its precision: it would allow the immune system to mount a more effective attack against tumors by removing the immune "brakes," all while leaving the beneficial, protective Treg cells intact and functional.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky emphasizes, highlighting MSK’s leading role in translating this fundamental discovery into clinical reality. Indeed, the concept has gained significant traction, and multiple clinical trials are currently underway at MSK and other leading institutions worldwide. These trials are rigorously testing the efficacy of CCR8-targeting antibodies, both as standalone therapies and in combination with existing immunotherapies, aiming to amplify anti-tumor responses. The new study on colorectal cancer profoundly strengthens the scientific rationale for deploying this selective strategy not only in CRC but potentially across a broader spectrum of cancers.
Similar Immune Patterns in a Broader Spectrum of Cancers
The implications of the MSK team’s work extend beyond colorectal cancer. To explore the broader applicability of their findings, the researchers undertook an ambitious analysis of a large dataset comprising T cells from 16 different cancer types. This comprehensive examination sought to determine whether the same crucial divisions between IL-10-positive and IL-10-negative Treg cells manifested elsewhere in the human body.
Their investigation yielded compelling results: similar patterns of distinct IL-10-positive and IL-10-negative Treg cell populations were identified in several other cancers. These included malignancies affecting the skin, as well as the delicate linings of the mouth, throat, and stomach. This discovery suggests a conserved immunological mechanism across various tissue types.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This commonality suggests that the immune systems in these "barrier tissues" might employ similar strategies to maintain balance and respond to threats, including cancerous transformation. Consequently, the team proposes that therapeutic strategies specifically designed to remove the harmful IL-10-negative Treg cells in colorectal cancer could very well prove effective against these other cancers that arise in similar barrier tissues, opening up exciting avenues for pan-cancer treatments.
A Different Immune Balance in Metastatic Disease
While the study offers profound insights into primary colorectal tumors, it also highlights the critical importance of considering the stage of disease. When the researchers turned their attention to colorectal cancer that had metastasized, specifically to the liver, they observed a significantly different immune landscape.
In these metastatic tumors, the balance between the two Treg subtypes was dramatically altered. The harmful IL-10-negative Treg cells greatly outnumbered the beneficial IL-10-positive cells, suggesting a shift towards a more immunosuppressive environment that favors distant tumor growth. Crucially, and in contrast to primary tumors where selective targeting is paramount, removing all Treg cells in the context of metastatic liver disease actually caused these tumors to shrink.
This stark difference underscores a vital message for therapeutic development: treatment strategies must be highly adaptable, accounting for both the specific tissue involved and the precise stage of the disease. A "one-size-fits-all" approach to Treg modulation is unlikely to be universally effective, emphasizing the need for precision oncology tailored to the dynamic nature of cancer progression.
Conclusion: A New Era for Colorectal Cancer Immunotherapy
The MSK study represents a monumental leap forward in cancer immunology. By meticulously dissecting the heterogeneity of regulatory T cells, the researchers have not only resolved a long-standing paradox in colorectal cancer but have also laid a robust foundation for developing more effective, precision immunotherapies. The shift from a monolithic view of Treg cells to a nuanced understanding of their opposing roles – with beneficial IL-10-positive cells and detrimental IL-10-negative cells – will undoubtedly reshape future therapeutic strategies.
The identification of CCR8 as a specific marker for the harmful Treg subtype offers a tangible and immediate target for drug development. The ongoing clinical trials evaluating CCR8-depleting antibodies represent the forefront of this new era in immunotherapy, promising to unleash the body’s intrinsic anti-cancer defenses in a highly selective manner. As this research expands to other barrier tissues and continues to inform strategies for metastatic disease, the impact of this breakthrough from Memorial Sloan Kettering Institute is poised to transform the lives of countless cancer patients.
Authors, Funding, and Disclosures
Additional authors who contributed to this significant research include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional resources played vital roles in the execution of this study, notably the Integrated Genomics Operation and the Single Cell Research Initiative at MSK.
Funding for this groundbreaking work was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Disclosures:
Dr. Rudensky serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
